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miR-125a, miR-139 and miR-324 
contribute to Urocortin protection 
against myocardial ischemia-
reperfusion injury
Ignacio Díaz1, Eva Calderón-Sánchez1, Raquel Del Toro1, Javier Ávila-Médina1,2, Eva Sánchez 
de Rojas-de Pedro1, Alejandro Domínguez-Rodríguez1,2, Juan Antonio Rosado3, Abdelkrim 
Hmadcha  4, Antonio Ordóñez1 & Tarik Smani  1,2
Urocortin 1 and 2 (Ucn-1 and Ucn-2) have established protective actions against myocardial ischemia-
reperfusion (I/R) injuries. However, little is known about their role in posttranscriptional regulation in 
the process of cardioprotection. Herein, we investigated whether microRNAs play a role in urocortin-
induced cardioprotection. Administration of Ucn-1 and Ucn-2 at the beginning of reperfusion 
significantly restored cardiac function, as evidenced ex vivo in Langendorff-perfused rat hearts and in 
vivo in rat subjected to I/R. Experiments using microarray and qRT-PCR determined that the addition 
of Ucn-1 at reperfusion modulated the expression of several miRNAs with unknown role in cardiac 
protection. Ucn-1 enhanced the expression of miR-125a-3p, miR-324-3p; meanwhile it decreased 
miR-139-3p. Similarly, intravenous infusion of Ucn-2 in rat model of I/R mimicked the effect of Ucn-1 
on miR-324-3p and miR-139-3p. The effect of Ucn-1 involves the activation of corticotropin-releasing 
factor receptor-2, Epac2 and ERK1/2. Moreover, the overexpression of miR-125a-3p, miR-324-3p and 
miR-139-3p promoted dysregulation of genes expression involved in cell death and apoptosis (BRCA1, 
BIM, STAT2), in cAMP and Ca2+ signaling (PDE4a, CASQ1), in cell stress (NFAT5, XBP1, MAP3K12) and 
in metabolism (CPT2, FoxO1, MTRF1, TAZ). Altogether, these data unveil a novel role of urocortin in 
myocardial protection, involving posttranscriptional regulation with miRNAs.
Ischemia induced by the interruption of heart blood flow evokes significant cardiac myocytes damages. 
Paradoxically, the subsequent reperfusion also activates various injury responses and further tissue lesions what 
is known as ischemia and reperfusion (I/R) injuries1. Advances in the understanding of pathophysiological mech-
anisms of I/R injury has identified a number of possible therapeutic targets and cardioprotectors such as ligands 
that activate RISK (reperfusion injury salvage kinase) or SAFE (survival activating factor enhancement) pathways; 
metoprolol, beta1-selective blocker; or cyclosporine-A among others drugs as reviewed recently2. Urocortin iso-
forms (Ucn-1, Ucn-2, and Ucn-3) have emerged as potential therapeutic agonists that improve heart performance 
and protect it from I/R injuries3, 4. In the cardiovascular system, urocortin binds to a G-protein-coupled receptor 
called CRF-R2 (corticotropin releasing factor receptor-2), whose activation enhances cAMP intracellular concen-
tration5, classically related to PKA activation. Now, it’s known that cAMP also activates Epac (exchange protein 
activated by cAMP), important regulator of several cAMP-regulated processes in heart6. We have previously 
shown that the addition of Ucn-1 improved intracellular Ca2+ concentration ([Ca2+]i) handling during I/R[7], 
and efficiently protected hearts from I/R damages by the modulation of apoptotic genes, CD40lg, Xiap and BAD, 
through the activation of Epac2 and ERK1/28.
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Recently, microRNAs (miRNAs) have emerged as important regulators of cardiovascular physiopathological 
processes9. miRNAs are non-coding single-stranded small RNA molecules with typically 18–25 nucleotides, act-
ing as negative regulators of gene expression by inhibiting the translation of mRNA and/or promoting mRNA 
degradation by complementary base-pairing with 3-untranslated regions (3-UTRs). miRNAs are involved in reg-
ulating cardiac function, such as contraction, heart growth and morphogenesis. Interestingly, several miRNAs 
modulate the expression of hundreds of key proteins involved in I/R injury and myocardial infarct10. For example, 
miR-21 is upregulated by ischemic postconditioning in mouse hearts, where it played a protective role through 
PTEN/Akt signaling pathway11. miR-133a and miR133b are implicated in cardioprotection during ischemic post-
conditioning12, and remote ischemic preconditioning13. In addition, miR-125b protected heart from I/R injury 
by the prevention of apoptotic signaling14, meanwhile miR-499 mediates cardiac protection against I/R injury by 
targeting the called programmed cell death 4 (PDCD4) during ischemia postconditioning15.
In the present study, we explored the involvement of miRNAs in the regulation of urocortin-induced heart 
protection. We observed that Ucn-1 differentially regulates the expression of miR-125a-3p, miR-324-3p and miR-
139-3p whose overexpression modulates several genes associated with a wide range of heart functions as cell 
stress, metabolism, cell survival and apoptosis.
Results
Urocortin-1 applied at the onset of reperfusion recovers hemodynamic performances in per-
fused rats hearts. The protective effect of Ucn-1 on heart contractility was examined ex vivo in Langendorff-
perfused rat hearts submitted to I/R. First, Table 1 shows that, in control hearts, the addition of 10 nM Ucn-1 
increased significantly heart contractility examined by the maximum derivative of left ventricular pressure (dP/
dt) and the left ventricular pressure (LVP), meanwhile it decreased the left ventricular end diastolic pressure 
(LVEDP) and the coronary vascular resistances (VR). Next, Fig. 1A shows that hearts exposed to 40 minutes of 
ischemia and 60 minutes of reperfusion (I/R) showed a significant decrease in dP/dt, indicating prominent loss 
in heart contractility. However, the administration of 10 nM Ucn-1, 5 minutes before reperfusion and maintained 
during 30 minutes, recovered completely heart’s contractility. The analysis of others hemodynamic parameters 
indicates that Ucn-1 improved the LVEDP (Fig. 1B), and the VR (Fig. 1C), whose progressive rise observed in 
reperfusion was prevented significantly by Ucn-1. Interestingly, the effects of Ucn-1 on heart performances were 
even maintained 60 minutes after washing out the peptide. Altogether, these data confirm that Ucn-1 addition 
at the onset of reperfusion recovers heart contractility, increases the ventricular diastolic loading and prevents 
coronary artery vasoconstriction, preserving effectively hearts’ performances.
Urocortin-1 regulates differentially the expression of cardiac miRNA in perfused hearts. Once 
the cardioprotective effect of Ucn-1 was confirmed, we sought to determine whether Ucn-1 (10 nM) might regu-
late post-transcriptional processes involved in cardioprotection during I/R. We performed a miRNA array anal-
ysis in hearts’ samples taken 1 hour after reperfusion from Langendorff-perfused hearts undergoing the same 
protocol as in Fig. 1. Table 2 shows that Ucn-1 promoted differential expression of several miRNAs. 29 of them 
were up and 9 were downregulated based on the threshold of fold change >1.3. The expression of 20 of these 
miRNAs was significantly different at p < 0.05 as shown in Fig. 2A.
To validate microarray results, we further examined the expression of miRNAs using qRT-PCR in samples 
from Langendorff-perfused hearts undergoing the same protocol as in Fig. 1. We focused on 6 miRNAs, miR-
30c-2, miR-29a-3p, miR-125a-3p, miR-139-3p, miR-320, and miR-324-3p, which role in cardioprotection is still 
unknown. As shown in Fig. 2B, Ucn-1 upregulated significantly the expression of miR-125a-3p and miR-324-3p, 
meanwhile it downregulated the expression of miR-139-3p. Nevertheless, changes in the levels of miR-29a-3p, 
miR-30c-2, and miR-320 were not significantly affected by Ucn-1.
Urocortin-1 modulates the expression of miR-125a-3p, miR-324-3p, and miR-139-3p in adult 
cardiac myocytes. To assess the endogenous expression of miR-125a-3p, miR-324-3p, and miR-139-3p, we 
treated isolated cardiac myocytes with different concentrations of Ucn-1 (2, 10 and 50 nM). Figure 3 shows that 
the expression of miR-125a-3p and miR-324 are increased significantly upon treatment with Ucn-1. In contrast, 
the level of miR-139-3p did not change significantly in cardiac myocytes incubated with any of the used Ucn-1 
doses. Next, we examined whether Ucn-1 may regulate the miRNAs expression in adult cardiac myocytes sub-
jected to I/R protocol. We found that, after I/R, the expression of miR-125a-3p (Fig. 4A) and miR-324-3p (Fig. 4B) 
decreased, whereas the expression of miR-139-3p increased (Fig. 4C). Interestingly, cells treatment with Ucn-1 
(10 nM) reverted the effect of I/R. Ucn-1 enhanced significantly the expression of both miR-125a-3p (Fig. 4A) 
Hemodynamics 
Paramaeters Control Ucn-1 (10 nM)
LVP (mmHg) 75.4 ± 5.6 130.9 ± 3.3
LVEDP (mmHg) 10.4 ± 0.1 −4.6 ± 2.9
+dP/dt (%) 100 195.9 ± 16.6
VR (%) 100 78.0 ± 6.5
Table 1. Summary data of changes in hemodynamics parameters produced by 10 nM Ucn-1 in Langendorff-
perfused hearts. Left ventricular pressure (LVP), left ventricular end diastolic pressure (LVEDP), maximum 
derivative of left ventricular pressure (+dP/dt), and vascular resistance (VR) were evaluated 20 minutes after 
Ucn-1 addition in 6 hearts.
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and miR-324-3p (Fig. 4B), meanwhile Ucn-1 downregulated miR-139-3p (Fig. 4C), confirming the data obtained 
in perfused hearts (Fig. 2B). Furthermore, as shown in Fig. 4A–C, these regulations of miRNAs by Ucn-1 were 
prevented in cardiac myocytes pretreated with astressin (Ast, 0.5 µM), the specific antagonist of CRF-R2 receptor. 
Therefore, Ucn-1 regulated significantly the expression of miRNAs through a mechanism involving CRF-R2.
Signaling pathway involved in urocortin-1 regulation of miRNAs. Recently, we have shown that 
ERK1/2 and Epac2 are involved in various cardioprotective effects of Ucn-18. Therefore, we examined the implica-
tion of ERK1/2 and Epac2 signaling pathway in Ucn-1 regulation of miR-125a-3p, miR-324-3p and miR-139-3p. 
Figure 4D shows that Ucn-1 (10 nM) addition to isolated cardiac myocytes under I/R enhanced the phospho-
rylation of both ERK p42 and p44 isoforms, which was potently reduced by PD 098059 (5 µM), specific inhibi-
tor of ERK1/28. Interestingly, cells pretreatment with PD 098059 prevented Ucn-1 upregulation of miR-125a-3p 
(Fig. 4A) and miR-324-3p (Fig. 4B), but it did not affect miR-139-3p (Fig. 4C) expression levels during cells 
reperfusion.
We further investigated Ucn-1 effect on Epac. Fig. 4E shows that Ucn-1 significantly increased the expres-
sion of Epac2 under I/R, which was prevented completely in cells pretreated with astressin. Furthermore, Epac2 
specific inhibition with ESI-05 (10 μM)16, blocked the effect of Ucn-1 on miR-324-3p (Fig. 4B) and miR-139-3p 
(Fig. 4C) regulation, but not miR-125a-3p expression (Fig. 4A). In addition, we found that the incubation of 
cardiac myocytes with 8CPT (10 μM), specific agonist of Epac1 and 216, mimicked mostly the effect of Ucn-1. 
The administration of 8CPT prevented I/R-induced changes on the expression of miR-324-3p and miR-139-3p; 
meanwhile it did not affect the change induced by I/R of miR-125a-3p expression.
Figure 1. Urocortin-1 recovers the hemodynamic function of Langendorff perfused rat hearts submitted 
to I/R. (A) Graph shows summary data of the contractility expressed as +dP/dt (%) in hearts subjected to 
ischemia/reperfusion protocol (I/R, full circle, n = 5), and in hearts treated with 10 nM Ucn-1 (+Ucn-1, open 
square, n = 5). Ucn-1 was applied 5 minutes before ischemia ends and during the first 30 minutes in reperfusion 
as indicated by area in grey. (B) Shows summary data of the left ventricular end diastolic pressure (LVEDP, 
mmHg) in the same conditions as in “A”. (C) Bar graph shows the changes in the mean of vascular resistances 
(VR, mmHg*min/ml). Values were taken 60 minute after reperfusion and were normalized to controls’ values. 
Data are means ± S.E.M. “*” and “**” indicate significance at p < 0.05 and p < 0.01 of I/R vs +Ucn-1.
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Altogether, these data suggest that Ucn-1 applied on the onset of reperfusion regulates differentially miR-
125a-3p, miR-324-3p and miR-139-3p through ERK1/2 and/or Epac2 signaling pathways.
Urocortin-2 infusion protects heart from I/R injuries and regulates the expression of miR-
NAs. To give more insight into the regulation of miRNAs by urocortin, we investigated its effect in vivo in rat 
experimental model of I/R provoked by transient LCA ligation. As Ucn-1 binds both to CRF-R1 and CRF-R2 
expressed in the brain, in the heart and the peripheral organs; therefore, instead of Ucn-1, we infused Ucn-2 
i.v. in tails’ rat 5 minutes before reperfusion to avoid its possible effects on central nervous system4. First, we 
confirmed that Ucn-2 and Ucn-1 have similar beneficial effects on contractility expressed as dP/dt and LVEDP 
in Langendorff-perfused heart (Supplement Fig. 1). Second, we evaluated the infusion of Ucn-2 at 50 µg/Kg, 
150 µg/Kg and 300 µg/Kg on cardiac contractility in I/R rat model. Figure 5A shows that temporary ligation of 
LCA reduced significantly the contractile capacity of heart, as observed by M-Mode echocardiography 24 hours 
after surgery. As shown in Fig. 5B the ejection fraction (EF) in I/R group was significantly reduced (50.8% ± 3.2) 
as compared with Sham (70.1% ± 2.8); whereas, EF recovered significantly after the infusion of Ucn-2 at 150 µg/
Kg (59.4% ± 3.1; Fig. 5A and B) and at 300 µg/Kg and (62.3% ± 1.2); but not when Ucn-2 was administrated at 
Gene ID Fold Change P value
miR-139-3p −3.09 0.003
miR-10a-5p −2.28 0.110
miR-324-3p 1.96 0.016
miR-145 1.88 0.144
miR-125a-3p 1.75 0.050
miR-494 1.66 0.256
miR-30c-2 1.64 0.035
miR-322 1.62 0.013
miR-181b 1.58 0.036
miR-320 1.51 0.014
miR-221 1.47 0.085
miR-126 −1.47 0.224
miR-500 1.44 0.027
miR-140 1.42 0.146
miR-15b −1.41 0.092
miR-99b 1.40 0.127
miR-466b 1.40 0.167
miR-99a 1.39 0.042
miR-128 1.38 0.226
miR-200c 1.36 0.023
miR-872 1.36 0.138
miR-450a 1.36 0.092
miR-24-2 1.35 0.076
miR-30e 1.35 0.053
miR-196c 1.35 0.067
miR-152 -1.35 0.253
miR-7a 1.34 0.010
miR-29a-3p 1.34 0.010
miR-324-5p 1.33 0.097
miR-598-3p 1.33 0.079
miR-361 1.32 0.011
miR-214 −1.31 0.015
let-7d 1.31 0.338
miR-25 1.31 0.093
miR-199a-5p −1.30 0.378
miR-342-3p −1.30 0.097
miR-137 −1.30 0.034
miR-340-5p 1.30 0.030
Table 2. miRNAs identified to be dysregulated. List of expressed miRNAs defined as dysregulated in miRNA 
microarray analysis in the Ucn-1 group as compared with the I/R group. miRNAs are classified by higher rate 
of change in Ucn-1 treatment versus untreated I/R. Expressed miRNAs are filtered based on “Fold change >1.3 
or <−1.3”. Bold letters is for miRNAs with significant changes at p < 0.05. I/R, ischemia/reperfusion; Ucn-1 
(10 nM) was applied 5 minutes before reperfusion.
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50 µg/Kg (51.8% ± 3.5). Similarly, as illustrated in Fig. 5C the shortening fraction (SF) was reduced in I/R group 
(51.1% ± 8.1) comparing with Sham; whereas the infusion of Ucn-2 at 150 µg/Kg (68.1% ± 8.9) and at 300 µg/
Kg (68.1% ± 1.1) recovered significantly the SF; but not when it was administrated at 50 µg/Kg (49.7% ± 5.4). 
Therefore, Ucn-2 was used at 150 µg/Kg to examine the expression of miR-125a-3p, miR-324-3p, and miR-139-3p 
in hearts’ samples taken 24 hours after surgery. Figure 5D and E shows that the expression of miR-125a-3p and 
miR-324-3p was downregulated in I/R group as compared to Sham. Ucn-2 infusion partially recovered the levels 
of miR-125a-3p (Fig. 5D); meanwhile, it reverted significantly the expression of miR-324-3p (Fig. 5E). In contrast, 
the expression of miR-139-3p was enhanced under I/R, but following the administration of Ucn-2 miR-139-3p 
was efficiently downregulated as illustrated in Fig. 5F. Altogether, these data confirm in I/R animal model that 
infusion of Ucn-2 right before reperfusion regulates the expression of, at least, significantly miR-324-3p and 
miR-139-3p.
The transfection of cardiac myocytes with lentivirus overexpressing miRNAs alters the expres-
sion of several genes. Using miRNA targets prediction, a group of candidate target genes were identified 
and selected for measurement of mRNA expression in neonatal rat ventricular cardiac myocytes (NRVMs) trans-
fected with lentivirus overexpressing miRNAs. Table 1 shows a list of selected genes known to regulate different 
cardiac pathophysiological processes related to cardioprotection, apoptosis and cell survival (e.g. BRCA1, IGF1, 
MTFR1, NRG1, STAT2, …); to adverse remodeling and fibrosis (e.g. NFAT5, CAMTA2, CREBBP, MAP3K12, 
COL5A2, DNAJB6, …); or to cell metabolism and stress (XBP1, MTFR1, FoxO1, TAZ, …), among other actions. 
First, we examined whether Ucn-1, under I/R, changes the expression of miRNAs in NRVMs in the same way as 
in adult cardiac myocytes. Figure 2 confirms that the addition of Ucn-1 in reperfusion significantly upregulated 
the expression of miR-125-3p and miR-324-3p, meanwhile it downregulated miR-139-3p. Second, Fig. 6A shows 
that the transfection of NRVMs with lentivirus over-expressing miR-125a-3p (LV-miR-125a-3p) significantly 
downregulated the expression of BRCA1, CPT2, MAP3K12, MTFR1, TAZ, and XBP1. Similarly, Fig. 6B shows 
that cardiac myocyte transfection with LV-miR-139-3p significantly attenuated the expression of PDE4a and 
FoxO1. However, as shown in Fig. 6C, cell transfection with LV-miR-324-3p unusually upregulated the expression 
of STAT2 and BIM genes, meanwhile it downregulated NFAT5 and CASQ1.
Furthermore, we examined whether Ucn-1 regulates the expression of these genes in adult cardiac myocytes 
under I/R. Figure 7 shows that the expression of BRCA1, STAT2, BIM, FoxO1 and MAP3K12 decreased under 
I/R, meanwhile cells treatment with Ucn-1 in reperfusion significantly reversed the expression of these genes. 
Moreover, Ucn-1 evoked changes in others genes regulated by miR-125a-3p, miR-324-3p and miR-139-3p were 
Figure 2. miRNAs detected by gene chip and qRT-PCR in perfused rat hearts. (A) List of up- and 
downregulated miRNAs detected by microarray in samples from Langendorff-perfused heart treated with 
Ucn-1 (10 nM) versus I/R (n = 4). (B) qRT-PCR conducted with samples from Langendorff-perfused heart 
treated with Ucn-1 vs I/R showing significant changes in the expression of miR-125a-3p, miR-139-3p and 
miR-324-3p but not of miR-30c-2, miR-29a-3p, or miR-320. Values are shown in logarithmic scale and are 
means ± S.E.M, (n = 6). “**” indicates significance at p < 0.01 as compared with I/R.
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not significantly different (data not shown). These data reveal that Ucn-1, through miR-125a-3p, miR-324-3p and 
miR-139-3p, might target multiple genes involved in different signaling pathway implicated in cardioprotection, 
which will induce synergetic beneficial effects.
Figure 3. Urocortin-1 regulates miR-125a-3p, miR-324-3p and miR-139-3p expression in isolated cardiac 
myocytes. Bar graphs showing fold changes in the expression of miR-125a-3p (A), miR-324-3p (B) and miR-
139-3p (C) in isolated cardiac myocytes treated 10 minutes with increasing concentrations of Ucn-1 (2, 10 and 
50 nM). Values are means ± S.E.M, (n = 4). “*” indicates significance at p < 0.05.
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Figure 4. Urocortin-1 regulates the expression of miRNAs in isolated cardiac myocytes through ERK1/2 and 
Epac2 activation. (A–C) Bar graphs show changes in the expression of miR-125a-3p (A), miR-324-3p (B) and 
miR-139-3p (C) in isolated cardiac myocytes treated with Ucn-1 (10 nM) in reperfusion. (D) Western blot and 
summary data showing ERK 1/2 phosphorylation in cells exposed to I/R (30 minutes/10 minutes). (E) Western 
blot and summary data showing Epac2 examined in cells exposed to I/R (30 minutes/18 hours each). “I/R” is for 
cells undergoing I/R protocols. “+Ast” is for cells subjected to I/R pre-treated 10 minutes with 0.5 µM astressin 
to inhibit CRF-R2 before the addition of Ucn-1. “+PD” is for cells pre-treated 10 minutes with 5 µM PD 098059 
to inhibit ERK1/2, before the addition of Ucn-1. “+ESI-05” is for cells pretreated 10 minutes with ESI-05 
(10 µM) to inhibit Epac2, before the addition of Ucn-1. “+8CPT” is for cells treated with 10 µM 8CPT at the 
onset of reperfusion. Values are shown in logarithmic scale and are means ± S.E.M, (n = 6–9 independent cells 
preparation). “*” and “**” indicate significance at p < 0.05 and p < 0.01.
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Figure 5. Infusion of urocortin-2 improves cardiac function in I/R and regulates the expression of miRNAs. 
(A) Cardiac function analyzed by echocardiography in M-mode 24 hours after surgery in three experimental 
models. Images are from “Sham” (n = 5); from “I/R” group corresponding to rats undergoing occlusion of the 
left coronary artery (LCA) for 40 minutes followed by reperfusion (n = 6); and for I/R rats infused with Ucn-2 
(150 µg/Kg) 5 minutes before reperfusion (n = 5). (B,C) Bar graphs summarize ejection fraction (EF, %) and 
shortening fraction (SF, %) measured in rats infused with 50, 150 or 300 µg/Kg of Ucn-2. (D–F) Bar graphs 
showing the expression of miR-125a-3p, miR-324-3p and miR-139-3p, respectively in hearts from Sham, I/R 
animal model, and from I/R rats infused with Ucn-2 (150 µg/Kg; +Ucn-2). Values are shown in logarithmic 
scale. Data show means ± S.E.M. (n = 5–7). “*” and “**” indicate significance at p < 0.05 and p < 0.01, 
respectively.
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Figure 6. Quantification of mRNA expression by qRT-PCR of microRNAs targets genes. Bar graphs show 
rate changes of genes mRNA expression assessed by qRT-PCR in neonatal rat cardiomyocytes infected 
with lentivirus overexpressing miR-125a-3p (A), 139-3p-3p (B) and miR-324-3p (C). Values are shown in 
logarithmic scale compared to cells infected with the GFP vector. Values are means ± S.E.M (n = 8). “*” and 
“**” indicate significance at p < 0.05 and p < 0.01, respectively.
Figure 7. Urocortin-1 regulates the expression of BRCA1, STAT2, BIM, FoxO1 and MAP3K12 in isolated 
cardiac myocytes under I/R. Bar graphs show rate changes of genes’ mRNA expression assessed by qRT-PCR 
in adult rat cardiac myocytes (control); in untreated cells undergoing I/R protocols myocytes (I/R); and in 
cells treated with Ucn-1 in I/R (10 nM, +Ucn1). Values are in logarithmic scale normalized to control and are 
means ± S.E.M (n = 8). “*” and “**” indicate significance at p < 0.05 and p < 0.01, respectively. “&” indicates 
significance between I/R and control at p < 0.05.
www.nature.com/scientificreports/
1 0SCIentIFIC RepoRts | 7: 8898  | DOI:10.1038/s41598-017-09198-x
Discussion
Damages produced by I/R damage are known to occur mainly during the first minutes of reperfusion17. Therefore, 
concomitant myocardial I/R injuries still remains a major challenge even after a successful revascularization of 
an ischemic heart1, 2. I/R impairment of heart’s function is due to multifactorial and complex processes, includ-
ing post-transcriptional gene regulation9, 10. Dysregulation of the expression of miRNA in the early phase of 
acute myocardial infarction (AMI) has been previously reported18, 19. Herein, we demonstrated that Ucn-1 and -2 
addition at the onset of reperfusion efficiently protected hearts from I/R injuries and modulated the expression 
of several miRNAs. The efficient protection exerted by Ucn-1 was observed in different experimental models 
of I/R, including isolated adult cardiac myocytes and ex vivo perfused heart. Ucn-1 recovered completely heart 
contractility, reduced coronary vascular resistance, and decreased LVEDP, indicating that Ucn-1 prevents heart’s 
dysfunction when applied at the onset of reperfusion. These effects were consistent with Ucn-1’s action when 
it was applied both in preconditioning and postconditioning protocols7, 8. Furthermore, we have evaluated the 
effect of urocortin in animal model subjected to temporary LCA occlusion, using Ucn-2 instead of Ucn-1 to 
minimize the effect of Ucn-1 through CRF-R1 in the central nervous system5. Ucn-1 and Ucn-2 have recognized 
similar biological effects associated with stress, appetite and feeding behavior, and with vascular tone regulation 
or with muscle remodeling20. Here, we showed that one single i.v. administration of Ucn-2 in rats exposed to I/R 
improved significantly cardiac contractility, in agreement with other studies that showed the beneficial effect of 
the infusion of urocortin peptides in different set of strategies to improve heart failure21–23.
In the current study, we demonstrated that the addition of Ucn-1 or Ucn-2 in the beginning of reperfusion 
changed the expression of miR-125a-3p, miR-324-3p, and miR-139-3p in different experimental models of I/R. 
The changes of miRNAs expression were mild but still significantly different as compared with changes induced 
by reperfusion. Ucn-1 inverted the effect of I/R and enhanced the expression of miR-125a-3p and miR-324-3p, 
meanwhile it decreased miR-139-3p expression. Similarly, Ucn-2 infusion in the animal model of I/R modu-
lated the expression of miR-324-3p and miR-139-3p, but it failed to recover completely miR-125a-3p levels. 
Interestingly, we found that Ucn-1 evoked miRNAs regulation through the activation of CRF-R2, ERK1/2, and 
Epac2, which is consistent with their role in cardioprotection8, 24. Here, we showed for the first time that Ucn-1 
enhanced the expression of Epac2, and confirmed that it stimulated ERK1/2 under I/R. Remarkably, the upregu-
lation of miR-125a-3p and miR-324 expression by Ucn-1 involved ERK1/2 activation; whereas, Epac2 was impli-
cated in miR-139-3p and miR-324 regulation. ERK1/2 regulation of miRNAs has been previously addressed as 
it modulated the expression of miR-133a in cardiac myocytes25, and miR-145 in vascular smooth muscle cells26. 
In contrast, little is known about Epac2 regulation of miRNAs in the heart. Recent studies indicated that Epac 
modulated the expression of miRNAs in other cell types, as it is the case of miR-20 in macrophages27, and miR-
451 in astrocytoma cells28.
The role of miR-125a-3p, miR-324-3p, and miR-139-3p in cardioprotection is still unclear. Previous reports 
demonstrated that circulating miR-125a-5p was associated with heart failure29, and it was significantly upregu-
lated in early phase of reperfusion in mice30. An other recent study demonstrated that miR-139-5p is downreg-
ulated in left ventricular tissue isolated from patients undergoing remote conditioning31. Our data indicates that 
the upregulation of miR-125a-3p in cardiac myocytes changed significantly the expression of different genes 
whose functions are associated with cell stress, metabolism, or cell survival and apoptosis. We determined that 
miR-125a-3p inhibited the expression of BRCA1, a well-known tumor suppressor with multiple interacting part-
ners and diverse biological functions32. In contrast, Ucn-1 increased BRCA1 expression under I/R in heart, which 
may be protective consistent with the role of BRCA1 in regulation of cardiac myocytes survival after myocardial 
infarction, its shielding of cardiac myocytes from DNA damage33, and its prevention of cardiac hypertrophy34. 
miR-125a-3p also reduced significantly the expression of MAP3K12 and XBP1, genes associated with cell stress. 
Meanwhile, Ucn-1 increased the expression of MAP3K12. MAP3K12, as a JNK signal pathway, is involved in 
apoptosis and is activated by exposure to environmental stresses such as oxidative stress35. XBP1 is a key regulator 
of sarcoplasmic reticulum stress found overexpressed in patients with ischemic cardiomyopathies36.
Furthermore, we observed that overexpression of miR-125a-3p inhibited others genes, as TAZ, CPT2 and 
MTFR1, related to mitochondria remodeling and metabolism. The inhibition of MTFR1 will be beneficial for 
heart protection, as it normally regulates mitochondrial fission and apoptosis in cardiac myocytes. Actually, 
MTFR1 knockdown reduced myocardial infarction sizes in mice37. A recent study suggested that impaired func-
tion of TAZ does not enhance susceptibility to ischemia-reperfusion injury38. Meanwhile, CPT2 downregulation 
disturbed the correct function of mitochondria metabolism in hearts, which will not help cells recovery in rep-
erfusion39. In fact, decreased CPT2 activity was observed in ischemic heart, which promoted the production of 
reactive oxygen species in cardiac mitochondria40.
On the other hand, we found that miR-139-3p overexpression reduced significantly the transcription factor 
FoxO1, which is essential for sustaining cardiac cells metabolism and viability41. FoxO1 downregulation and 
its posttranslational modulation was also involved in the alteration of heart’s function, including collagen and 
protein metabolism dysregulation in a mouse model of post-ischemic heart failure42. Herein, we demonstrated 
that Ucn-1 decreased miR-139-3p’s levels and increased the expression of FoxO1 under I/R, which consequently 
will be beneficial for cardiac myocytes survival. In fact, FoxO1 reduced cardiac myocytes stress by upregulating 
antioxidant, anti-apoptotic, and autophagy genes43. miR-139-3p, but not Ucn-1, also inhibited the expression of 
PDE4a, a critical protein involved in cAMP hydrolysis and heart contraction44. PDE4 selective inhibitors were 
evaluated in the context of cardioprotection, but their effects were not conclusive45. They increased cAMP levels 
induced by catecholamine but they also promoted arrhythmias46. In this way, Ucn-1 induced miR-139-3p inhibi-
tion under I/R might be beneficial, as it will avoid the associated detrimental effects of PDE4 inhibition, although 
the effect of Ucn-1 on the expression of PDE4 needs further confirmation.
We also observed that miR-324-3p and Ucn-1 increased the expression of STAT2 and BIM (BCL2L11) 
genes; both of them involved in apoptosis and cardioprotection. Initially, miRNAs effect was thought to mediate 
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downregulation in a one-way process, decreasing mRNA stability and/or translational inhibition. Nevertheless, 
as discussed recently, several evidences demonstrated that some miRNAs could upregulate genes expression in 
specific cell types and conditions with distinct transcripts and proteins47, consistent with our findings. Previous 
studies have demonstrated that different STAT members modulate the apoptotic program. STAT1 was involved in 
apoptosis and in pro-inflammatory process in cardiac myocyte under I/R48; and STAT3 was implicated in Ucn-1 
mediated cardioprotection49. However, little is known regarding the role of STAT2 in cardioprotection. In the 
same way, the increase of BIM expression by miR-324-3p suggests the initiation of apoptosis by Ucn-1, which is 
reliable with our recent finding demonstrating that Ucn-1 enhanced the expression of a pro-apoptotic gene, BAD, 
under I/R8. In contrast, other reports have shown that BIM is downregulated by miR-2450, and miR-22151, which 
inhibited apoptosis. The beneficial role of apoptosis in detriment of necrosis to reduce the impact of I/R lesions 
has been largely discussed52. Apoptosis is a highly regulated energy-consuming process required for controlled 
and programmed cell death, which will certainly be beneficial to limit cardiac cell loss and posterior inflamma-
tion processes in I/R. Moreover, miR-324-3p overexpression downregulated NFAT5 and CASQ1 genes, whose 
role in cardioprotection are unknown. Although, NFAT5 expression was increased during protection against 
hypertonicity during I/R in rat kidney53; whereas, CASQ1 is a calcium-regulating protein involved in cardiac 
myocyte contraction, whose alteration was associated with Ca2+ overload during I/R54.
To conclude, this study highlights unidentified effects of Ucn-1 on transcriptional and posttranscriptional 
processes in heart subjected to I/R. Ucn-1 affords acute cardioprotective effects, but also modulates the expression 
of miR-125a-3p, miR-324-3p, and miR-139-3p, whose overexpression alters the expression of different genes. 
Further experiments will be important to corroborate the potential of these miRNAs as therapeutic targets for 
cardioprotection that might be a useful strategy for long-term heart protection.
Materials and Methods
All the experiments with animals were performed in accordance with the recommendations of the Royal Decree 
53/2013 in agreement to the Directive 2010/63/EU of the European Parliament and approved by the local Ethics 
Committee on human Research of the “Virgen del Rocio” University Hospital of Seville and the Animal Research 
Committee of the University of Seville.
Global ischemia/reperfusion (I/R) in Langendorff-perfused rat heart. Adult male Wistar rats 
weighing 250–300 g were anaesthetized by intraperitoneal administration of an overdose of sodium thiopental 
(200 mg/Kg) as described previously7. The hearts were quickly removed, mounted on the aortic cannula of the 
Langendorff perfusion system apparatus and perfused with an oxygenated Krebs-Henseleit (KH) buffer (118 mM 
NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, and 5 mM glucose) as 
described previously7, 8. The buffer was equilibrated with 95% O2 and 5% CO2. To obtain an isovolumetrically 
beating preparation, a latex balloon filled with water and connected by a catheter to a transducer (Abbott, IR), was 
inserted through the left atrium into the left ventricle and inflated to provide an end-diastolic pressure between 
8 and 12 mmHg. Before starting with experimental protocols, the isolated hearts were set at a mean arterial 
pressure of 60–80 mmHg and were allowed to stabilize at 37 °C for 40 to 60 minutes. Chart Powerlab software 
(AD Instruments) was used for continuous recording throughout the experiments of heart rate, and maximum 
positive derivative of left ventricular pressure (+dP/dt). The heart contractility under different treatments was 
evaluated, in rate-paced hearts, by the analysis of +dP/dt, which corresponds to percent (%) increase of +dP/dt 
normalized to basal +dP/dt after stabilization period. I/R was conducted in isolated hearts by closing the perfu-
sion to hearts and period of reperfusion started by the restoration of the flow.
To evaluate Ucn-1 or -2 effect on heart undergoing I/R, we considered the following experimental groups: 
Group 1 (ischemia/reperfusion, I/R): after stabilization, hearts were exposed to global ischemia during 40 minutes 
followed by 1 hour reperfusion with freshly oxygenated KH solution. Group 2 (I/R + Ucn-1 or Ucn-2): 10 nM of 
Ucn was applied at the beginning of reperfusion using an external pump with low flow. Urocortin was maintained 
during the first 30 minutes of reperfusion. Hearts were kept in reperfusion during additional 90 minutes.
Rat model for myocardial ischemia and reperfusion (I/R). Male Wistar rats weighing 250 ± 50 grams 
were anesthetized with a mixture of O2/sevoflurane 2%, then with anesthesia (50 mg/kg ketamine plus 8 mg/
kg xylazine i.p) as described previously54. A small animal ventilator was used (Harvard Apparatus, Model 683, 
Massachusetts, NC) with a tidal volume (Vt) of 1.60–2 ml and 75–80 ventilations per minute. A left thoracotomy 
was performed in the intercostal space between the third and fourth ribs, followed by a pericardiotomy. The left 
coronary artery (LCA) was occluded with a 6-0 ProleneTM silk suture (Ethicon, Spain) and tied off below the 
level of the left atria appendage and over a small tube placed into the suture for the posterior release of the occlu-
sion, for a correct reperfusion. LCA occlusion was confirmed by visual observation of cyanosis and ST-segment 
elevation by continuous ECG monitoring and the reperfusion by reversal of these effects. After 40 minutes of 
LCA ligation, reperfusion was initiated by releasing the knot and removing the tube, and was confirmed by the 
appearance of epicardial hyperemic response and by ECG recovery. The chest cavity was closed and the air was 
expelled from the chest, sevoflurane administration was switched off and the animal was supplied with O2 until 
reflexes were detected. Analgesia was induced with meloxicam (1 mg/Kg) administered subcutaneously. Animal 
was placed in a cage on a heating pad until fully conscious recovery. Animals were randomly subjected to either 
LCA ligation or sham operation experimenting 5% mortality during the intervention. The survival rate in all 
groups after Ucn-2 or saline treatment was 100%. Immediately after surgery, animals were further assigned to the 
following experimental groups:
Group 1 (I/R; n = 6): ischemia was produced by LCA ligation during 40 minutes and the vehicle (saline 0,9% 
NaCl) administration by tail vein injection 5 minutes before reperfusion. Group 2 (I/R + Ucn-2; n = 5): ischemia 
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was produced by LCA ligation during 40 minutes and an intravenous (i.v.) dose of Ucn-2 (50, 150, or 300 µg/Kg) 
was administered by tail vein injection 5 minutes before reperfusion. Group 3 (Sham; n = 5): operated rats under-
went the same surgical procedure without coronary ligation.
Samples from I/R animal experimental models’ hearts were taken 24 hours after surgery depending on the 
experimental protocol.
Cardiac function. Transthoracic echocardiographic analyses, using a VevoTM 2100 ultrasound system with 
transducer MS250 with a frequency range of 13-24 MHz (VisualSonicsTM, Canada), were undertaken to detect 
changes in cardiac performances55. The basal cardiac function was analyzed 24 hours after surgery in light anes-
thetized rat with 2.0% sevoflurane. M-Mode images of the left ventricle at the level of the papillary muscles were 
obtained, and different functional hemodynamic parameters were evaluated. Images acquisition and analyses 
were done in a blind manner.
Isolation of adult ventricular myocytes and simulated I/R protocol. The hearts were removed and 
mounted on a Langendorff perfusion apparatus. Ventricular myocytes were isolated using collagenase type II (251 
IU/mL; Worthington Biochemical, Lakewood, NJ, USA) as described previously7. Subsequently, isolated cells 
were filtered, centrifuged and suspended in Tyrode solution containing (en mM): 130 NaCl, 1 CaCl2, 0.5 MgCl2, 
5.4 KCl, 22 glucose, 25 HEPES, 0.4 NaH2PO4, 5 NaHCO3; pH was adjusted to 7.4 with NaOH. Cardiac myocytes 
were plated in control solution containing 1.8 mM CaCl2 at 37 °C, and were submitted to a protocol of I/R using a 
simulated ischemic solution (mM): 142 NaCl, 3.6 KCl, 1.2 MgCl2, 1.8 CaCl2, 5 NaHCO3, 20 Hepes, 20 Lactate-Na, 
20 sucrose (pH 6.22). Cells were then placed during 30 minutes in an incubator at 1% O2 and 5% CO2. Afterward, 
cells were incubated in control solution were maintained in an incubator at 21% O2 and 5% CO2 during 18 hours. 
All the experiments were performed on Ca2+-tolerant rod-shaped myocytes at 37 °C. We considered the follow-
ing experimental groups: Group 1 (Control): Untreated cardiac myocytes. Group 2 (I/R): After stabilization in 
control solution, cells were exposed to simulated ischemia solution during 30 minutes and reperfused for 18 hours 
with freshly control solution. Group 3 (Ucn-1): Same as group 2, but Ucn-1 (10 nM) was in reperfusion. Group 
4, (8CPT): Same as group 3 but 8CPT (10 µM, specific agonist of Epac2) was applied instead of Ucn-1. Group 5, 
6 and 7: Cells treated with either astressin (10 µM, CRF-R2 inhibitor), ESI-05 (10 µM, Epac2 inhibitor) or PD 
098059 (5 µM, ERK1/2 inhibitor), 10 minutes before the addition of Ucn-1 (10 nM) following the same protocol 
as in group 3.
Neonatal ventricular myocytes. Neonatal rat ventricular cardiomyocytes (NRVMs) were isolated from 
the hearts of 1 to 3 days-old Wistar rats. The heads were cut off, the auricles were discarded and the ventricu-
lar cells were dispersed by successive enzymatic digestion with 0.125% trypsin and 0.1% collagenase. NRVMs 
(1 × 106/ml) were seeded into 6-well plates. The primary ventricular cardiomyocytes were cultured in Dulbecco’s 
Modified Eagle Medium DMEM/medium 199 (4:1) supplemented with 10% horse serum, 15% fetal bovine serum 
(FBS), 1% glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin for 24 hours. On the next day, medium was 
replaced and cells were grown with 1% FBS. Approximately 48 hours after isolation, the cells displayed as conflu-
ent monolayer with spontaneous contractile activity. Then, the cells were cultured in medium without FBS until 
its use. NRVMs were subjected to the same protocol of I/R as in adult cardiac myocyte for miRNAs’ experiment.
Western Blotting. Protein samples were extracted from cultured and treated cardiac myocytes. 40 μg of pro-
tein were subjected to SDS-PAGE (10% acrylamide) and electrotransferred onto PVDF membranes. Membranes 
were probed overnight at 4 °C with specific primary antibodies in TTBS with 1% of BSA. Phospho-ERK1/2 and 
ERK1/2 primary antibodies were from Cell Signaling (Massachusetts, USA), Epac2 antibody was from BIOLOG 
LSI (Germany). Detection was performed with the enhanced chemiluminiscence reagent ECL-plus (Amersham 
Bioscience, UK) in the ImageQuant LAS 4000 mini (GE Healthcare, UK). For quantification, the images were 
analyzed with “Image J” software using alpha-tubulin (Sigma-Aldrich, Spain) as housekeeping loading control.
Lentivirus production and cardiac cells transfections. To ensure miRNAs mimics cells deliv-
ery, Lentivirus-expressing miR-125a-3p (LV-miR-125a-3p), Lentivirus-miR-139-3p (LV-miR-139-3p) and 
Lentivirus-miR-324-3p (LV-miR-324-3p) were constructed by cloning the pre-microRNA sequence in plasmid 
(pSIN-DUAL-GFP). Lentivirus with scramble sequence was used as control (LV-miR-control). To produce the 
lentiviral particles the plasmid pSIN-DUAL, together with p8.91 and pVSV plasmids were cotransfected in HEK 
cells using Calphos Kit (Cultek, Madrid, Spain), then purified and titled prior to their use in NRVMs cultures. 
The efficacy of the transfection of cultured NRVMs with lentiviral vectors conjugated with GFP was confirmed 
by immunofluorescence and qRT-PCR analyzes 24 hours after cells transfection (Supplement Fig. 3). Lentivirus 
expressing scrambled miRNAs was used as a control.
RNA extraction. Total RNA was extracted from cultured cardiac myocytes using the RNeasy kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. 1 µg of RNA were retro-transcribed to cDNA 
with the TaqMan microRNA Reverse Transcription Kit (Qiagen, Hilden, Germany). qRT-PCRs were per-
formed using a Prism 7900HT Sequence Detection System, TaqMan primers and probes technologies (Applied 
Biosystems, California, USA). Fold change in gene expression was calculated using the comparative cycle thresh-
old CT method (2−ΔΔCT method) using U87 as endogenous control.
Microarray analysis. Microarray of miRNAs was conducted using RNA samples from Langendorff 
perfused-hearts submitted to I/R and from heart treated with 10 nM Ucn-1 (n = 4 for each group). “Rat 
microRNA Microarray” from Agilent (Agilent Technologies, California, USA) was used following manufactur-
er’s instructions, and miRNA-expression profiling was performed using a chip containing 350 mature miRNAs. 
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Microarray analysis was done using an Agilent’s 60-mer SurePrint scanner to acquire the microarray images, 
which were subsequently processed with GenePix Pro software 7.0 (Molecular Devices, California, USA) to gen-
erate the expression data in GPR (Genepix Result File) format, all according to manufacture’s instructions. The 
background corrected intensity values by algorithm normexp were used for analysis, and quantile normalization 
was employed. Expressed genes were filtered on the basis of standard deviation between four biological replicates 
at p < 0.05 and fold change >1.3.
To determine the biological functions and pathways regulated by miRNAs data were subjected to a bioinfor-
matics analysis using miRBASE, PicTar, Targetscan database (http//www.mirBase.org, www.pictar.org and www.
Targetscan.org) to predict target genes. Genes were selected based on: i) their appearance in the top 10 in each 
software; ii) their presence of at least Log values of the used software; and iii) their confirmed relation with dif-
ferent cardiac pathophysiological processes linked to cardioprotection, adverse remodeling, apoptosis or fibrosis 
among other actions.
Statistical analysis. Data analysis was carried out using SigmaPlot software, version 11.0. A sample size 
calculation was performed prior the start of this study. Group data are presented as mean ± S.E.M. Single or 
paired Student’s t test was used to determine the statistical significance of the obtained data. The significance 
between multiple groups was evaluated using ANOVA followed by Tukey multiple comparison post-hoc tests. 
Data marked by * and ** were considered significantly different at p < 0.05, and p < 0.01 respectively.
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